JP7237287B2 - 単一ドメイン抗体に基づくbcmaキメラ抗原受容体及びその使用 - Google Patents
単一ドメイン抗体に基づくbcmaキメラ抗原受容体及びその使用 Download PDFInfo
- Publication number
- JP7237287B2 JP7237287B2 JP2021534411A JP2021534411A JP7237287B2 JP 7237287 B2 JP7237287 B2 JP 7237287B2 JP 2021534411 A JP2021534411 A JP 2021534411A JP 2021534411 A JP2021534411 A JP 2021534411A JP 7237287 B2 JP7237287 B2 JP 7237287B2
- Authority
- JP
- Japan
- Prior art keywords
- car
- cells
- bcma
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title claims description 102
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title claims description 102
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims description 100
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims description 32
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title claims 9
- 210000004027 cell Anatomy 0.000 claims description 92
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 239000013598 vector Substances 0.000 claims description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 239000012642 immune effector Substances 0.000 claims description 29
- 229940121354 immunomodulator Drugs 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 230000004068 intracellular signaling Effects 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- -1 CD3e Proteins 0.000 claims description 16
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 15
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 11
- 201000003444 follicular lymphoma Diseases 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 9
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 102000017578 LAG3 Human genes 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 8
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 8
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 7
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 108091008874 T cell receptors Proteins 0.000 claims description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100035793 CD83 antigen Human genes 0.000 claims description 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 4
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 4
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 201000003791 MALT lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims description 4
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 230000001589 lymphoproliferative effect Effects 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 3
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 102000036639 antigens Human genes 0.000 description 31
- 201000000050 myeloid neoplasm Diseases 0.000 description 16
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 10
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 241001416177 Vicugna pacos Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 210000004180 plasmocyte Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000011357 CAR T-cell therapy Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000023761 AL amyloidosis Diseases 0.000 description 3
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010053869 POEMS syndrome Diseases 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000046935 human TNFRSF17 Human genes 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000009724 equine infectious anemia Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091005966 Type III transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願人は、遺伝子操作の手段によって特異的アミノ酸配列を含む単一ドメイン抗体を設計し、結合ドメイン(BCMA結合ドメイン)として単一ドメイン抗体を使用することによって、キメラ抗原受容体(CAR)を構築した。キメラ抗原受容体を含む免疫細胞(例えばCART細胞)が関連する腫瘍への強い殺傷能力及び特異性を有することが、研究を介して見出された。特に、CARは健康なヒトTリンパ球にインビトロで効率的に形質導入され、BCMA陽性標的細胞に対する強い殺傷効果を生じ、インビボの実験においても、以下の強い殺傷効果を示す。ルシフェラーゼによりトランスフェクションされたMM.1S細胞の使用による検出のために、原発性骨髄腫を持つマウスモデルが確立され、投与3日の後に大部分の蛍光は消滅し、CART細胞が優れた治療効果をインビボで有することを指摘する。
1)BCMA単一ドメイン抗体ライブラリーの構築
健康な成体のアルパカを、Beijing Yiqiao Shenzhou Ltd.から購入したBCMA抗原により、複数の皮下注射によって首及び背中で免疫した。免疫に際して、等体積の抗原及びフロイントアジュバントを、4~6の免疫のために加えた。注射部位での質量の吸収をトラッキング及び観察して、正確な免疫を確認した。免疫間の間隔は7~15日であった。第4の免疫後に、血液サンプルを収集して、抗原の免疫力価を決定した。力価が10000倍(ELISA法)を超えた場合に、血液サンプル(約100ml)を収集してリンパ球を単離し、RNAを抽出し、それをcDNAへ逆転写した。アルパカ重鎖抗体の可変領域断片VHHを2回のPCRによって増幅した。VHH断片をファージディスプレイライブラリーへと構築し、単一ドメイン抗体を保有する遺伝子断片の生成物を、コンピテントセルの中へ形質転換して、単一ドメイン抗体免疫ライブラリーを得た。
単一ドメイン抗体分子をファージディスプレイ技術によってファージの表面上に提示させ、次いでスクリーニングして抗原特異的単一ドメイン抗体を得た。ファージ酵素結合免疫吸着アッセイ(ELISA)によって、抗原を100μg/mLの最終的な濃度へ100mMのNaHCO3(pH8.0)により希釈し、100μLを96ウェルプレートの中へコーティングし、4℃で一晩放置した。PBSにより洗浄し、1%のスキムミルクによりシーリングした後に、ファージを添加して、1~2時間インキュベーションした。次いで、抗原特異的ファージを溶出し、アンピシリンを含有するLB培養プレート上にコーティング及び培養したTG1細胞を感染させた。複数ラウンドのスクリーニングによって、濃縮を徐々に達成した。多数の陽性クローンをELISA検出のために選択し、陽性クローンをシーケンスした。配列アライメントに従って、ユニークなクローンを同定し、フレーム領域(FR)及び相補性決定領域(CDR)へと分割した。
2つの遺伝子セグメントをTaihe Biotechnology Co.,Ltd.によって合成した。1つは、実施例1において調製したBCMA sdAb I中に含有される配列番号:15のヌクレオチド配列であり;他のものは、デザインされた第2世代CAR構造遺伝子である(CD8aヒンジ領域、膜貫通ドメイン+4-1BB共刺激ドメイン+CD3ζ細胞内シグナリングドメインであり、これらのドメインを含有する第2世代CAR構造遺伝子をコードするヌクレオチド配列は、配列番号:16において記載される)。合成遺伝子を得た後に、分子クローニングを遂行して、BCMA CARを構築した。配列番号:15及び配列番号:16のPCR産物をPCRによって得た。オーバーラップPCRを使用して、2つの断片の連結によって形成されるBCMA CAR遺伝子を得た(そのヌクレオチド配列は配列番号:12において記載される)。レンチウイルスプレベクター及びBCMA CAR遺伝子を酵素によって消化し、接続し、形質転換した。クローンをピックアップし、プラスミドを抽出した。シーケンシングを遂行して、レンチウイルスベクタープレ-レンチ-EF1-BCMAの正確な配列を得た。
ウイルスパッケージングの前日に、293T細胞(ATCCから購入した)を、トリプシンによって消化し、1×107細胞/ディッシュで10cmのディッシュの中へ播種した。細胞のトランスフェクションに際して、実施例2において調製したプレ-レンチ-EF1-BCMAプラスミドに加えて、各々のプラスミドは、パッケージングプラスミドpsPAX2、pMD2.0Gと共にコトランスフェクションされることが必要とされる。それらのうちで、5μgのプレ-レンチ-EF1-BCMA、3.75μgのpsPAX2プラスミド、及び1.25μgのpMD2.0Gプラスミドを使用した。トランスフェクションに際して、上記の3つのプラスミドの混合物を500μlのMEM培地の中へ添加した。分離したマイクロ遠心分離チューブ中に、25μLのLipofectamine(リポソーム)2000試薬を500μlのMEMの培地の中へ添加した。次いで、希釈したトランスフェクション試薬を、上記の希釈したプラスミドに滴加し、良く混合し、遠心分離し、20分間の室温で放置した。最終的に、プラスミド及びトランスフェクション試薬の混合物を10cmの培養用ディッシュの中へ添加し、10回穏やかに振盪し、良く混合し、インキュベーターの中へ置いた。トランスフェクションの3日後に、ウイルスを収穫した。10mlのウイルス含有培養液上清を50mlの遠心分離チューブの中へ移し、1250rpmで4℃で5分間遠心分離して、死んだ293T細胞を除去した。次いで、ウイルス含有上清を濾過し、濃縮し、サブパッケージングし、使用のために-80℃で保存した。
1)Tリンパ球の調製
滅菌環境において、10mlの静脈血をボランティアから採血した。50mlの遠心分離チューブへ、10mlのヒトリンパ球単離試薬(Dakewei Bioengineering Co.,Ltd.)を添加した。血液を、電動ピペットガンにより遠心分離チューブの中へ壁に沿ってゆっくり添加した。遠心分離チューブを遠心分離チューブの中へ置き、700gで22℃で25分間遠心分離した。遠心分離の完了後に、PBMCは、上部の血漿層と分離した溶液との間の白色膜層で濃縮していた。白色膜層を、パスツールピペットにより別の遠心分離チューブの中へ可能な限り吸引した(30mlの1640培地を添加する)。分離した溶液を吸引しないように注意した。250g、22℃、10分間。上部の液体を廃棄した。細胞を3mlの1640培地中で再懸濁し、T細胞精製のためにカウントした。
一晩の培養後に、実施例3においてMOI=2で調製したプレ-レンチ-EF1-BCMAウイルス溶液を、感染のために一晩添加した。2日目に、1mlの新鮮培地を補足した。3日目に、T細胞は十分に活性化し、迅速に分裂増殖した。その時に、T細胞を25cm2培養フラスコの中へ移動させた。感染の5日後に、T細胞の表面上でのBCMA CAR分子の発現効率を、生体標識BCMA Fcタンパク質により決定して、特異的なBCMA CART細胞を産生する。細胞膜の表面上でのCARの発現をフローサイトメトリーによって検出した。BCMA CART細胞の表面上でのBCMA CAR分子の発現のフローサイトメトリー検出結果を、図1中に示す。図1中の結果は、実施例4において調製したBCMA CART細胞におけるCAR発現効率が50%を超えることを示す。
1)インビトロ機能の評価
多発性骨髄腫MM.1S細胞及び骨髄性白血病K562細胞(ATCCから購入した)に、フローサイトメトリーを行った。結果を図2中に示す。図2の結果は、BCMA分子がMM.1S細胞において有効に発現されるが、K562細胞において発現されないことを指摘する。
ヒト多発性骨髄腫細胞株MM.1Sをルシフェラーゼレポーター遺伝子を発現するように形質導入して、MM.1S-lucを得た。10%のウシ胎仔血清(FBS)を含有する1640を、インキュベーター中で5%のCO2中で従来通りに37℃でインキュベーションした。MM.1S-luc細胞株を、尾静脈(50匹のマウス、オス半数及びメス半数)経由で、1.5×106細胞/200μlのPBSで、17日間注射した。次いで、すべての動物を画像化した。均一な担腫瘍マウスを実験群の中へ登録し、5つの群(オス半数及びメス半数、各々の群中に8匹のマウス)、すなわち細胞外液群、モックT群、そして、BCMA CARTの低用量群、中用量群、及び高用量群へとランダムに割り当てた。それらのうちで、細胞外液群に尾静脈経由で細胞外液を注射し、モックT群に尾静脈経由でモックT細胞を注射し、BCMA CARTの低用量群、中用量群、及び高用量群に、尾静脈経由で実施例4において調製したBCMA CART細胞を注射した。
Claims (25)
- BCMA結合ドメイン、膜貫通ドメイン、1つまたは複数の共刺激ドメイン、及び細胞内シグナリングドメインを含む、キメラ抗原受容体(CAR)であって、
前記BCMA結合ドメインが、重鎖相補性決定領域1(HCDR1)、重鎖相補性決定領域2(HCDR2)、及び重鎖相補性決定領域3(HCDR3)を含み、前記HCDR1のアミノ酸配列が配列番号:1において記載され、前記HCDR2のアミノ酸配列が配列番号:2において記載され、前記HCDR3のアミノ酸配列が配列番号:3において記載され、
前記BCMA結合ドメインが単一ドメイン抗体である、CAR。 - 前記BCMA結合ドメインが、配列番号:4において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項1に記載のCAR。
- 前記膜貫通ドメインが、T細胞受容体のα鎖、β鎖もしくはζ鎖、CD28、CD3e、CD45、CD4、CD5、CD8a、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137、及びCD154から選択されるタンパク質に由来するポリペプチドを含む、請求項1または2に記載のCAR。
- 前記膜貫通ドメインが、配列番号:5において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項1~3のいずれか1項に記載のCAR。
- 前記BCMA結合ドメインが、ヒンジ領域を介して膜貫通ドメインへ連結される、請求項1~4のいずれか1項に記載のCAR。
- 前記ヒンジ領域が、配列番号:6において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項5に記載のCAR。
- 前記1つまたは複数の共刺激ドメインが、CARD11、CD2、CD7、CD27、CD28、CD30、CD40、CD54(ICAM)、CD83、CD134(OX40)、CD137(4-1BB)、CD150(SLAMF1)、CD152(CTLA4)、CD223(LAG3)、CD270(HVEM)、CD273(PD-L2)、CD274(PD-L1)、CD278(ICOS)、DAP10、LAT、NKG2C、SLP76、TRIM、及びZAP70から選択される共刺激分子に由来する、請求項1~6のいずれか1項に記載のCAR。
- 前記共刺激ドメインが、配列番号:7において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項1~7のいずれか1項に記載のCAR。
- 前記細胞内シグナリングドメインがCD3ζのシグナリングドメインを含む、請求項1~8のいずれか1項に記載のCAR。
- 前記細胞内シグナリングドメインが、配列番号:8において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項1~9のいずれか1項に記載のCAR。
- リーダー配列をさらに含み、前記リーダー配列が配列番号:9において記載されるアミノ酸配列、またはその機能的なバリアントを含む、請求項1~10のいずれか1項に記載のCAR。
- 配列番号:10において記載されるアミノ酸配列、配列番号:11において記載されるアミノ酸配列、またはそれらの機能的なバリアントを含む、請求項1~11のいずれか1項に記載のCAR。
- 請求項1~12のいずれか1項に記載の前記CARをコードする、単離核酸分子。
- 配列番号:12において記載される核酸配列、または配列番号:13において記載される核酸配列を含む、CARをコードする単離核酸分子。
- 請求項13または14に記載の前記核酸分子を含む、ベクター。
- DNAベクター、RNAベクター、プラスミド、レンチウイルスベクター、アデノウイルスベクター、及びレトロウイルスベクターから選択される、請求項15に記載のベクター。
- EF1プロモーターをさらに含み、前記EF1プロモーターが配列番号:14において記載される配列を含む、請求項15または16に記載のベクター。
- 請求項1~12のいずれか1項に記載の前記CAR、請求項13または14に記載の前記核酸分子、または請求項15~17のいずれか1項に記載の前記ベクターを含む、免疫エフェクター細胞。
- Tリンパ球及びナチュラルキラー(NK)細胞から選択される、請求項18に記載の免疫エフェクター細胞。
- 請求項15~17のいずれか1項に記載の前記ベクターを免疫エフェクター細胞の中へ導入することを含む、免疫エフェクター細胞を調製する方法。
- 前記免疫エフェクター細胞が、Tリンパ球及びナチュラルキラー(NK)細胞から選択される、請求項20に記載の方法。
- 請求項1~12のいずれか1項に記載のCAR、請求項13または14に記載の核酸分子、請求項15~17のいずれか1項に記載のベクター、または請求項18または19に記載の免疫エフェクター細胞を含む、医薬組成物。
- BCMAの発現と関連する疾患または障害の治療のための、請求項22に記載の医薬組成物。
- BCMAの発現と関連する前記疾患または障害が、癌または悪性腫瘍である、請求項23に記載の医薬組成物。
- BCMAの発現と関連する前記疾患または障害が、B細胞急性リンパ芽球性白血病、T細胞急性リンパ芽球性白血病、急性リンパ芽球性白血病、慢性骨髄性白血病、慢性リンパ性白血病、B細胞前リンパ球性白血病、芽球性形質細胞様樹状細胞腫、バーキットリンパ腫、びまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、有毛細胞白血病、小細胞型濾胞性リンパ腫または大細胞型濾胞性リンパ腫、悪性リンパ増殖性病態、MALTリンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、多発性骨髄腫、骨髄異形成及び骨髄異形成症候群、非ホジキンリンパ腫、形質芽球性リンパ腫、形質細胞様樹状細胞腫、ヴァルデンストレームマクログロブリン血症、前立腺癌、膵臓癌、肺癌、骨髄腫、MGUS、形質細胞腫、全身性アミロイド軽鎖アミロイドーシス、ならびにPOEMS症候群からなる群から選択される、請求項23または24に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810972053.8 | 2018-08-24 | ||
CN201810972053.8A CN109134665B (zh) | 2018-08-24 | 2018-08-24 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
PCT/CN2019/095505 WO2020038146A1 (zh) | 2018-08-24 | 2019-07-10 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535756A JP2021535756A (ja) | 2021-12-23 |
JP7237287B2 true JP7237287B2 (ja) | 2023-03-13 |
Family
ID=64827759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021534411A Active JP7237287B2 (ja) | 2018-08-24 | 2019-07-10 | 単一ドメイン抗体に基づくbcmaキメラ抗原受容体及びその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220218746A1 (ja) |
EP (1) | EP3842462A4 (ja) |
JP (1) | JP7237287B2 (ja) |
KR (1) | KR102223873B1 (ja) |
CN (1) | CN109134665B (ja) |
AU (1) | AU2019325036B2 (ja) |
BR (1) | BR112021003408A2 (ja) |
CA (1) | CA3109320C (ja) |
EA (1) | EA202190607A1 (ja) |
SG (1) | SG11202101685XA (ja) |
WO (1) | WO2020038146A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
CA3110262C (en) * | 2018-08-24 | 2024-05-14 | Shenzhen Pregene Biopharma Co. Ltd. | Anti-bcma single domain antibodies and application thereof |
CN109678961A (zh) * | 2019-01-15 | 2019-04-26 | 深圳市南科生物工程有限公司 | 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用 |
US20220144948A1 (en) * | 2019-01-29 | 2022-05-12 | Shanghai Jiao Tong University | Chimeric antigen receptor and use thereof |
CN109942708B (zh) * | 2019-03-28 | 2021-01-05 | 上海科棋药业科技有限公司 | 一种抗bcma的单域抗体及其应用 |
CN111171160B (zh) * | 2020-02-14 | 2022-05-17 | 四川大学华西医院 | 基于TGF-β改造的嵌合抗原受体及其修饰的免疫细胞 |
CN111333729B (zh) * | 2020-03-17 | 2022-12-06 | 深圳市南科生物工程有限公司 | 抗b细胞成熟抗原的纳米抗体及应用 |
CN111848798B (zh) * | 2020-07-27 | 2022-05-13 | 源道隆(苏州)医学科技有限公司 | 可结合bcma的纳米抗体及其应用 |
CN111909271B (zh) * | 2020-08-12 | 2021-03-23 | 深圳市茵冠生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及其应用 |
CN111925451B (zh) * | 2020-10-12 | 2021-01-29 | 佑仁细胞工程(浙江)有限公司 | 一种靶向bcma的嵌合抗原受体(car)及其应用 |
CN112592927B (zh) * | 2020-12-22 | 2024-06-11 | 上海科棋药业科技有限公司 | 一种同时靶向cd19和bcma的双靶点嵌合抗原受体及其应用 |
CN116390954A (zh) * | 2020-12-29 | 2023-07-04 | 宁波茂行生物医药科技有限公司 | 靶向bcma的单域抗体 |
CN113087798B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
CN114149505B (zh) * | 2021-01-12 | 2022-11-04 | 北京门罗生物科技有限公司 | 治疗b细胞相关疾病的免疫细胞、制备方法及其应用 |
CN112830971B (zh) * | 2021-02-08 | 2022-07-29 | 华道(上海)生物医药有限公司 | 一种抗bcma的抗原结合片段及其应用 |
CN113265001B (zh) * | 2021-02-08 | 2022-07-29 | 华道(上海)生物医药有限公司 | 一种抗b细胞成熟抗原的纳米抗体及其应用 |
CN117924497A (zh) * | 2021-03-22 | 2024-04-26 | 浙江纳米抗体技术中心有限公司 | 一种靶向bcma的纳米抗体及其应用 |
WO2022228429A1 (zh) * | 2021-04-27 | 2022-11-03 | 原启生物科技(上海)有限责任公司 | 靶向bcma的嵌合抗原受体及其应用 |
WO2023098846A1 (zh) * | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
CN114195896B (zh) * | 2021-12-06 | 2022-07-05 | 东莞清实生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及其应用 |
WO2024011104A1 (en) * | 2022-07-05 | 2024-01-11 | Neomics Pharmaceuticals Llc | Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain |
CN117384299B (zh) * | 2022-11-01 | 2024-04-30 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用 |
CN117186229B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用 |
CN115947853B (zh) * | 2022-12-26 | 2024-06-28 | 河北森朗生物科技有限公司 | 靶向bcma的纳米抗体、嵌合抗原受体及其应用 |
CN116239692B (zh) * | 2023-01-13 | 2023-11-17 | 北京艺妙神州医药科技有限公司 | 分离的抗体、包含该抗体的car及其用途 |
CN116396389B (zh) * | 2023-05-05 | 2024-01-23 | 成都优赛诺生物科技有限公司 | 一种靶向bcma的单域抗体、嵌合抗原受体及其应用 |
CN117534763B (zh) * | 2023-12-28 | 2024-03-26 | 康维众和(中山)生物药业有限公司 | 抗bcma的纳米抗体及其制备方法与应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
WO2017025038A1 (en) | 2015-08-11 | 2017-02-16 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof |
WO2017053889A2 (en) | 2015-09-23 | 2017-03-30 | Precision Immunotherapy, Inc. | Flt3 directed car cells for immunotherapy |
CN106749678A (zh) | 2017-01-09 | 2017-05-31 | 北京普瑞金科技有限公司 | Her2 car重组慢病毒载体及其构建方法与应用 |
JP2017527271A (ja) | 2014-07-21 | 2017-09-21 | ノバルティス アーゲー | ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置 |
JP2017537925A (ja) | 2014-12-05 | 2017-12-21 | メモリアル スローン−ケタリング キャンサー センター | B細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018085690A1 (en) | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015248956B2 (en) * | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
PT3628687T (pt) * | 2014-12-12 | 2021-10-20 | Bluebird Bio Inc | Recetores do antigénio quimérico bcma |
EP3270960A4 (en) * | 2015-03-20 | 2018-08-08 | Bluebird Bio, Inc. | Vector formulations |
SG10202007177XA (en) * | 2015-08-03 | 2020-09-29 | Engmab Sarl | Monoclonal antibodies against bcma |
EP3408297A2 (en) * | 2016-01-29 | 2018-12-05 | Med Manor Organics, (P) Ltd | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
CN105837693A (zh) * | 2016-05-30 | 2016-08-10 | 李斯文 | 一种基于bcma的抗原嵌合受体及其制备方法和应用 |
CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
-
2018
- 2018-08-24 CN CN201810972053.8A patent/CN109134665B/zh active Active
-
2019
- 2019-04-04 KR KR1020190039819A patent/KR102223873B1/ko active IP Right Grant
- 2019-07-10 CA CA3109320A patent/CA3109320C/en active Active
- 2019-07-10 WO PCT/CN2019/095505 patent/WO2020038146A1/zh active Application Filing
- 2019-07-10 AU AU2019325036A patent/AU2019325036B2/en active Active
- 2019-07-10 EA EA202190607A patent/EA202190607A1/ru unknown
- 2019-07-10 BR BR112021003408-0A patent/BR112021003408A2/pt unknown
- 2019-07-10 EP EP19852889.5A patent/EP3842462A4/en active Pending
- 2019-07-10 JP JP2021534411A patent/JP7237287B2/ja active Active
- 2019-07-10 US US17/270,775 patent/US20220218746A1/en active Pending
- 2019-07-10 SG SG11202101685XA patent/SG11202101685XA/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
JP2017527271A (ja) | 2014-07-21 | 2017-09-21 | ノバルティス アーゲー | ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置 |
JP2017537925A (ja) | 2014-12-05 | 2017-12-21 | メモリアル スローン−ケタリング キャンサー センター | B細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
WO2017025038A1 (en) | 2015-08-11 | 2017-02-16 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof |
WO2017053889A2 (en) | 2015-09-23 | 2017-03-30 | Precision Immunotherapy, Inc. | Flt3 directed car cells for immunotherapy |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018085690A1 (en) | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
CN106749678A (zh) | 2017-01-09 | 2017-05-31 | 北京普瑞金科技有限公司 | Her2 car重组慢病毒载体及其构建方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3109320C (en) | 2023-10-31 |
WO2020038146A1 (zh) | 2020-02-27 |
JP2021535756A (ja) | 2021-12-23 |
SG11202101685XA (en) | 2021-03-30 |
EP3842462A1 (en) | 2021-06-30 |
BR112021003408A2 (pt) | 2021-05-18 |
US20220218746A1 (en) | 2022-07-14 |
KR102223873B1 (ko) | 2021-03-08 |
CA3109320A1 (en) | 2020-02-27 |
CN109134665B (zh) | 2021-06-11 |
KR20200023165A (ko) | 2020-03-04 |
AU2019325036A1 (en) | 2021-04-22 |
EA202190607A1 (ru) | 2021-05-28 |
CN109134665A (zh) | 2019-01-04 |
AU2019325036B2 (en) | 2023-10-05 |
EP3842462A4 (en) | 2022-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7237287B2 (ja) | 単一ドメイン抗体に基づくbcmaキメラ抗原受容体及びその使用 | |
JP7280828B2 (ja) | Bcmaを標的とする抗体およびその使用 | |
US12048718B2 (en) | Chimeric antigen receptor and CAR-T cells that bind BCMA | |
US11090334B2 (en) | Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
WO2021057823A1 (en) | Ror1 specific chimeric antigen receptors and their therapeutic applications | |
WO2021043169A1 (zh) | 特异性结合b细胞成熟抗原的抗体及其用途 | |
CN110950953A (zh) | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 | |
CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
US20230242638A1 (en) | Chimeric antigen receptor targeting cldn18.2 and use thereof | |
WO2022007650A1 (zh) | 靶向bcma和cd19的嵌合抗原受体car或car构建体及其应用 | |
WO2021057866A1 (zh) | 一种单域抗体及包含抗体结构的嵌合抗原受体 | |
WO2020135559A1 (en) | Cd30-binding moieties, chimeric antigen receptors, and uses thereof | |
JP2022527935A (ja) | Cd3結合分子 | |
AU2021338819A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
WO2022116952A1 (zh) | 靶向cd70的抗原结合蛋白及其应用 | |
US11643468B2 (en) | Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders | |
JP2023522112A (ja) | 汎用型ヒト化car19-dnt細胞を製造する技術およびその使用 | |
EA045097B1 (ru) | Химерный антигенный рецептор для bcma на основе однодоменного антитела и его применение | |
WO2024103251A1 (zh) | 抗afp/hla02 tcr样抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210430 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7237287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |